Intragraft immune cells: accomplices or antagonists of recipient-derived macrophages in allograft fibrosis?

Cell Mol Life Sci. 2023 Jul 3;80(7):195. doi: 10.1007/s00018-023-04846-0.

Abstract

Organ fibrosis caused by chronic allograft rejection is a major concern in the field of transplantation. Macrophage-to-myofibroblast transition plays a critical role in chronic allograft fibrosis. Adaptive immune cells (such as B and CD4+ T cells) and innate immune cells (such as neutrophils and innate lymphoid cells) participate in the occurrence of recipient-derived macrophages transformed to myofibroblasts by secreting cytokines, which eventually leads to fibrosis of the transplanted organ. This review provides an update on the latest progress in understanding the plasticity of recipient-derived macrophages in chronic allograft rejection. We discuss here the immune mechanisms of allograft fibrosis and review the reaction of immune cells in allograft. The interactions between immune cells and the process of myofibroblast formulation are being considered for the potential therapeutic targets of chronic allograft fibrosis. Therefore, research on this topic seems to provide novel clues for developing strategies for preventing and treating allograft fibrosis.

Keywords: Allotransplantation; Colony-stimulating factor 1; Extracellular matrix; Interleukin-22; M2 macrophages; Monocytes.

Publication types

  • Review

MeSH terms

  • Allografts
  • Fibrosis
  • Humans
  • Immunity, Innate*
  • Lymphocytes*
  • Macrophages